Overview

Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Deep-vein thrombosis (DVT) is a common but under-diagnosed medical condition that occurs when a thrombus forms in one of the large veins, usually in the lower limbs, leading to either partial or complete blocked circulation. The condition may progress to severe health complications, such as pulmonary embolism (PE), if not diagnosed and treated in a timely and effective manner. The goal of the therapy for lower-extremity DVT is to prevent the extension of thrombus and pulmonary embolism in the short term and to prevent recurrent events in the long-term. Although anticoagulant therapy decreases the risk of recurrent thrombosis, the treatment also increases the risk for major hemorrhage. This trial aims to optimize the current medical knowledge on the effectiveness and safety of two low molecular weight heparins, bemiparin and enoxaparin in the treatment of deep vein thrombosis.
Phase:
Phase 3
Details
Lead Sponsor:
Berlin-Chemie AG Menarini Group
Treatments:
Bemiparin
Enoxaparin
Enoxaparin sodium
Heparin, Low-Molecular-Weight